Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2025
Event: Announcement of a conference call to discuss financial results for the first quarter ended March 31, 2025, and provide a corporate update.
Key Financial Metrics
This filing is a procedural announcement regarding an upcoming conference call. It does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The filing serves solely to notify investors of the scheduled conference call on May 8, 2025, at 4:30 p.m. Eastern Time.
Guidance, Outlook, and Risks
Management Commentary: Management intends to discuss Q1 2025 results and provide a corporate update during the upcoming conference call.
Guidance and Risks: This filing does not contain updated guidance, specific risk factors, or details on contingencies. Investors are directed to the press release (Exhibit 99.1) and the upcoming call for further details.
Investor Verification Checklist
- Verify the date and time of the conference call (May 8, 2025, 4:30 p.m. ET).
- Review the attached press release (Exhibit 99.1) for any preliminary highlights.
- Monitor the upcoming earnings release for actual Q1 2025 financial figures, as they are not included in this 8-K.
- Confirm the company's status as an emerging growth company (indicated as unchecked in the filing).